While the coronavirus has impacted millions of Americans across the United States, it has hit the elderly population particularly hard. In fact, more than 40 percent of coronavirus deaths in the U.S. have been linked to long-term care facilities, according to a New York Times survey. In an effort to bring those numbers down, pharmaceutical company Eli Lilly, in partnership with the National Institutes of Health (NIH), has just launched a late-stage antibody treatment trial focusing on residents and staff at nursing homes.
"COVID-19 has had a devastating impact on nursing home residents," Lilly's chief scientific officer Daniel Skovronsky said in a statement. "We're working as fast as we can to create medicines that might stop the spread of the virus to these vulnerable individuals."
The trial is expected to enroll up to 2,400 participants who live or work at a facility and have recently been diagnosed with the disease. The trial will evaluate the safety and success of using LY-CoV555, a potent, neutralizing antibody that works against the spike protein of the novel coronavirus. The trial will look at whether a single dose of the antibody treatment reduces the rate of infection over four weeks as well as symptoms over eight weeks.
"The importance of these kinds of therapies for people like the elderly or immunocompromised is that they can provide the hope and the safety net that these people really need right now," said Andrew Adams, vice president of new therapeutic modalities & COVID-19 research at Eli Lilly, who is overseeing the trial. "I think people in those populations are really desperate and looking for something to help with the coronavirus."
Eli Lilly is taking its trial on the road with customized mobile research units that can travel directly to areas that are experiencing outbreaks.
"This is an interesting solution, to bring the medicine to these vulnerable patients," said Adams. "This lets us be flexible and move these trials around the country, tracking these trials as we come across them."
Adams said he is hoping Eli Lilly will have results on the efficacy of these antibodies in the fourth quarter of this year. Even if successful, though, he says research for a vaccine needs to continue.
"These have to be thought of as more of a bridge, where a vaccine provides long-term protection in terms of years of immunity, where we will provide hopefully in the range of months with these types of treatments. We hope this to be a short-term bridge to the long-term effective vaccination," he said.
A deal was reached as the COP26 Summit in Glasgow came to a close. Dr. Katharine Hayhoe, Chief Scientist at the Nature Conservancy and Author of 'Saving Us: A Climate Scientist's Case for Hope and Healing in a Divided World,' joined Cheddar News' Closing Bell to discuss the deal.
Over the years many people have gotten into the act of living a sustainable life all in the hopes of helping to protect and save the plant. However, some argue that living in this kind of fashion is expensive and only accessible to the wealthy. Editor at Large at CNET Farnoosh Torabi, joined Cheddar to discuss more.
As we move into the colder months in the U.S., health experts are warning of a more active flu season than last year, sounding the alarm on what many are calling a 'twindemic.' Dr. Syra Madad, infectious disease epidemiologist, joined Cheddar's 'Search for the Cure' to discuss the intersection of the flu season with the Covid-19 pandemic.
The UN climate summit wrapped up over the weekend after days of negotiations over the summit's final agreement. The agreement pushes countries to reassess their climate goals by the end of next year, do more for countries facing the worst effects of climate change, and also calls for a "phase down" of coal and other fossil fuel subsidies. The White House praised the agreement, but underscored the feelings of many world leaders by saying it isn't enough.
Deborah Brosnan, climate expert and president of Deborah Brosnan and Associates, joined Cheddar's News Wrap to discuss.
Dr. Joseph Sellers, President of the Medical Society of the State of New York and Pediatrician at Basset Medical Group, joined Cheddar News for an update on vaccinations for kids under 12 now that the rollout has officially begun.
President Biden is under some pressure from members of his own party over rising gas prices. Senate Majority Leader Chuck Schumer has called for the president to utilize oil reserves to lower gas prices ahead of the holiday season, as gas prices are currently at a seven-year high. Energy Workforce & Technology Council CEO Leslie Beyer joins Cheddar News' Closing Bell to discuss.
Russia is being blamed for putting the International Space Station and its crew at risk after it fired a missile during a weapons test at a non-functional satellite. NASA has said that the debris from the explosion could potentially orbit the Earth for decades.
Cases of covid-19 are climbing in the Upper Midwest, Southwest, and parts of the Northeast. The seven-day national average is sitting at roughly 82,000 new cases which is an 11 percent jump from the week before. Dr. Amesh Adalja, Infectious Disease, Specialist, Sr. Scholar at Johns Hopkins Center for Health Security joined Cheddar's Opening Bell to discuss this recent uptick ahead of the holiday season.
Jill is joined by Baker Machado to talk all things infrastructure: where will the money go and who’s in charge? Plus, Sesame Street has its first Asian-American muppet. And a trailer for the trailer for Spiderman. Huh?
Booking.com has unveiled a first-of-its-kind sustainable travel designation for properties that might be on the itinerary of a climate-conscious traveler. CEO Glenn Fogel explained to Cheddar the key metrics a location has to achieve to earn a sustainability badge. Waste handling, energy and greenhouse gases, water usage, local community support, and protection of nature were the five top areas of concern he addressed, with an additional subset of 32 measures that properties can implement.
